EGFR antagonist, Cetuximab is used in cases of

Cetuximab and pemtumomab are directed against the epidermal growth factor receptor (EGFR), a transmembrane glycoprotein involved in signaling pathways affecting growth and proliferation of tumor cells. Both cetuximab and pemtumomab, when given alone, have been shown to benefit a small propoion of previously treated patients